BLA 761306 · Eli Lilly and CO
Ebglyss
Lebrikizumab-Lbkz · Injection · Interleukin-13 Antagonist
NovelCDER novel approval, Sep 13, 2024: To treat moderate-to-severe atopic dermatitis
Last checked: Nov 19, 2026Latest source record: Jun 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Sep 13, 2024
Approved uses
2
Original approval plus efficacy supplements
Registered trials
50
27 Phase 3, 5 recruiting
FAERS reports
2,280
254 serious, 12 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 30, 2026.
EBGLYSS is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids. EBGLYSS ® is an interleukin-13 antagonist indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids. ( 1 )
Mechanism: Lebrikizumab-lbkz is an IgG4 monoclonal antibody that binds with high affinity and slow off-rate to interleukin (IL)-13 and allows IL-13 to bind to IL-13Rα1 but inhibits human IL-13 signaling through the IL-4Rα/IL-13Rα1 receptor complex. IL-13 is a naturally occurring cytokine that is involved in Type 2 inflammation, which is an important component in the pathogenesis of atopic dermatitis. Lebrikizumab-lbkz inhibits IL-13-induced responses including the release of proinflammatory cytokines, chemokines and IgE. Lebrikizumab-lbkz-bound IL-13 can still bind IL-13Rα2 allowing subsequent...
Therapeutic areas: Immunology and inflammation · Dermatology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 9, 2026 Supplement 6 · Efficacy LetterLabel
- Sep 13, 2024 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
- EBGLYSS · LEBRIKIZUMAB-LBKZ 250MG/2ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lebrikizumab" as an intervention, any sponsor and status, largest first.
- Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)Pivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT04392154 · 1,153 participants · Start Jun 15, 2020 · Primary completion Jul 19, 2024
Drug: Lebrikizumab · For: Atopic Dermatitis
Sites: Anniston, Alabama; Birmingham, Alabama; Scottsdale, Arizona · 321 sites in all
- A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller MedicationPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01867125 · 1,081 participants · Start Jul 25, 2013 · Primary completion Dec 28, 2016
Drug: Lebrikizumab; Placebo · For: Asthma
Sites: Pell City, Alabama; Tucson, Arizona; Fountain Valley, California · 181 sites in all
- A Study of Lebrikizumab in Participants With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller MedicationPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01868061 · 1,068 participants · Start Jul 31, 2013 · Primary completion Jan 2, 2017
Drug: Lebrikizumab; Placebo · For: Asthma
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 232 sites in all
- A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic DermatitisPivotal-lookingActive, not recruiting
Almirall, S.A.Industry
NCT06526182 · 520 participants (planned) · Start Jul 3, 2024 · Primary completion Apr 25, 2027
Drug: Lebrikizumab · For: Dermatitis, Atopic; Eczema
Sites: Alicante, Spain; Barcelona, Spain; Granada, Spain · 4 sites in all
- A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06338995 · 510 participants (planned) · Start Apr 29, 2024 · Primary completion May 2027
Drug: LY3650150; Placebo and 1 more · For: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Sites: Birmingham, Alabama; Huntsville, Alabama; Tucson, Arizona · 202 sites in all
- A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01872689 · 505 participants · Start Oct 13, 2013 · Primary completion Jul 28, 2017
Drug: Lebrikizumab; Pirfenidone and 1 more · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 112 sites in all
- A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)Pivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06339008 · 450 participants (planned) · Start Apr 26, 2024 · Primary completion Oct 22, 2026
Drug: LY3650150; Placebo and 1 more · For: Perennial Allergic Rhinitis (PAR)
Sites: Huntington Beach, California; Inglewood, California; Laguna Niguel, California · 74 sites in all
- Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic DermatitisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT04178967 · 445 participants · Start Oct 29, 2019 · Primary completion Jul 12, 2021
Drug: Lebrikizumab · For: Atopic Dermatitis
Sites: Scottsdale, Arizona; Rogers, Arkansas; Bakersfield, California · 89 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pruritus264
- injection site pain260
- drug ineffective241
- rash178
- conjunctivitis154
- dermatitis atopic149
- eczema135
- erythema109
- dry skin79
- incorrect dose administered72
- ocular hyperaemia62
- skin exfoliation62
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 3 |
| 2023 | 5 |
| 2024 | 71 |
| 2025 | 1,020 |
| 2026 | 1,181 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu AWL, Wong MM, Rayner DG, et al. · J Allergy Clin Immunol 2023 · Systematic Review, Network Meta-Analysis
- Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Focused update: Guidelines of care for the management of atopic dermatitis in adults.
Davis DMR, Frazer-Green L, Alikhan A, et al. · J Am Acad Dermatol 2025 · Systematic Review, Practice Guideline
- Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update.
Drucker AM, Lam M, Prieto-Merino D, et al. · JAMA Dermatol 2024 · Systematic Review, Network Meta-Analysis
- Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. · Br J Dermatol 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).
Simpson EL, Gooderham M, Wollenberg A, et al. · JAMA Dermatol 2023 · Randomized Controlled Trial, Multicenter Study
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.